A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Rasagiline in Subjects With Progressive Supranuclear Palsy (Phase III).

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Rasagiline in Subjects With Progressive Supranuclear Palsy (Phase III).

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2016

At a glance

  • Drugs Rasagiline (Primary)
  • Indications Progressive supranuclear palsy
  • Focus Therapeutic Use
  • Acronyms PROSPERA
  • Most Recent Events

    • 20 Jun 2013 Results presented at the 17th International Congress of Parkinson's Disease and Movement Disorders].
    • 07 Nov 2012 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 12 Oct 2012 Status changed from completed to suspended as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top